The Procter & Gamble Company (PG)[Tv]

Key Developments

• Procter & Gamble acquires Thorne HealthTech for $3.8 billion, marking a defining strategic pivot into the science-driven wellness and longevity space—a high-risk, high-reward move aimed at capturing Gen Z and millennial consumers who prioritize clinical credibility, digital engagement, and personalized health solutions.
• PG achieves 70th consecutive annual dividend increase in April 2026, reinforcing its status as a true Dividend King and underscoring its ironclad commitment to shareholder returns despite deteriorating growth momentum.
• PG successfully challenges Quanovate’s fertility monitor marketing claims, leading to the company’s voluntary withdrawal—highlighting PG’s aggressive use of regulatory power to defend its market position in health tech, raising questions about competitive fairness and innovation suppression.
• Procter & Gamble posts flat organic sales growth driven solely by pricing, not volume, revealing a fundamental erosion in demand and shrinking market share, indicating its traditional brands are losing relevance in a fast-moving, innovation-led consumer landscape.
• Market consensus assigns PG a D-grade rating from Seeking Alpha, placing it alongside underperforming peers like Altria and Colgate-Palmolive—a damning signal that investor confidence is eroding due to stagnation in innovation and growth, despite strong fundamentals.